U.S. stock benchmarks rose Friday morning to kick off 2021’s final three months, following heavy selling that closed a bruising September for investors.
Friday’s upbeat tone was partly attributed to news on Merck & Co.’s MRK, +7.92% experimental antiviral drug, developed as a treatment for COVID-19 with partner Ridgeback Biotherapeutics, which reduced the risk of hospitalization or death in at risk adult patients with mild-to-moderate COVID by about 50% in an interim analysis of data from a Phase 3 trial.
How are stock-market futures trading?
- The Dow Jones Industrial Average DJIA, +0.28% rose 188 points, or 0.5%, to 34,013.
- The S&P 500 index SPX, -0.02% picked up 5 points, or 0.1%, to 4,313.
- The Nasdaq Composite Index COMP, -0.35% slipped less than 0.1% to reach 14,435, after briefly touching an intraday high at 14,504, near Friday’s open.
On Thursday, the Dow fell 547 points, or 1.59%, to 33844, the S&P 500 declined 52 points, or 1.19%, to 4308, and the Nasdaq Composite dropped 64 points, or 0.44%, to 14449.
For September, the Dow lost 4.3%, the S&P 500 fell 4.8% and snapped a seven-month winning streak, and the Nasdaq Composite was off 5.3%, its worst September in a decade. For the quarter, the Dow fell 1.9%, the S&P 500 was up 0.2% and the Nasdaq Composite rose 0.4%.
What’s driving the markets?
The report on Merck’s experimental drug was helping bulls make a case for buying in the first trading session in October, a seasonally weak month, but selling in healthcare and technology stocks was capping Wall Street’s early enthusiasm.
Jittery investors dumped stocks Thursday, taking little comfort from news of a short-term spending bill to avert a government shutdown while debt-limit wrangling was set to continue. Speaker Nancy Pelosi late Thursday called off a planned vote in the U.S. House of Representatives on a $1 trillion bipartisan infrastructure bill, as Democratic lawmakers can’t agree on other linked spending proposals.
Apart from the rough quarter and month, the S&P 500 index was looking at a roughly 3% drop for the week as of Thursday, which would mark the worst weekly performance since January 2021, according to FactSet. A nearly 4% decline for the Nasdaq Composite for the week so far would mark its worst since February.
The S&P 500 is now 5% off its Sep. 2 high, but still up 14% year-to-date.
“As we head into the final quarter of 2021 the gains year to date are still pretty decent, which raises the question, how much more is left in the tank, and whether this October will live up to the reputation of Octobers past, and deliver a huge curveball, as well as giving investors an anxiety attack,” said Michael Hewson, chief market analyst at CMC Markets U.K.
“There’s certainly plenty to be concerned about from surging energy prices, supply-chain disruptions, and concerns about more persistent inflation,” he said in a note to clients.
Energy prices have been soaring, including in Europe, with shortages on the continent as well as in Asia, where China has been hit by power cuts and outages. Traders are betting on higher crude demand after a report Thursday said China has ordered state-owned energy companies to secure winter supplies at all costs. U.S. CL00, -0.57% and Brent crude oil prices BRN00, -0.36% were down around 0.4% each on Friday.
The U.S. dollar has surged 1% this week so far, driven by expectations that the Federal Reserve could be ready to curtail its accommodative monetary stance put in place to fight the COVID-19 pandemic fallout. But the U.S. dollar DXY, -0.11% was moving lower against major rivals on Friday, as measured by the ICE Dollar Index, while the 10-year Treasury yield TMUBMUSD10Y, 1.481% dipped 4 basis points to 1.487%.
Markets didn’t react to reports on U.S. personal spending and incomes, which provided further evidence that the cost of goods and services are rising, with the rate of U.S. inflation at a 30-year high, and all signs pointing to price pressures snaking into next year.
The personal consumption expenditure price index climbed 0,4% in August, the government said Friday, marking the sixth straight big increase. The rate of inflation in the 12 months ended in August edged up to 4.3% from 4.2%—the highest rate since 1991, when George H.W. Bush was president.
A final reading from IHS Markit showed that U.S. manufacturing PMI rose to 60.7 in September from an 60.5 initial estimate. A reading of 50 or better indicates improving conditions.
Following that, the Institute for Supply Management manufacturing index for September is due at 10 a.m., along with construction spending.
Which companies are in focus?
- Shares of Merck were up over 8%. after trials showed that 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization, compared with 14.1% of patients given a placebo. Through Day 29, no patients given molnupiravir died, compared with eight patients who died on placebo. The company is now planning to submit an application for an emergency use authorization for the treatment from the Food and Drug Administration and will also seek it from other regulatory bodies around the world. The interim analysis looked at data from 775 patients enrolled in the trial on or before Aug. 5. Merck is planning to produce 10 million courses of treatment by year-end with more to come in 2022.